Gilead's twice-yearly HIV prevention shot was 100% effective in women and almost as good in men. The company will offer cheap generic versions in 120 poor countries, mostly in Africa and Asia. However, it has excluded most of Latin America, raising concerns about missed opportunities to stop the disease in these regions.
